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Allogeneic hematopoietic cell transplantation (alloHCT) is a curative therapy for hematologic disorders
including acute lymphoblastic and myeloid leukemia, chronic lymphocytic and myeloid leukemia, Hodgkin’s
and non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndrome. To determine the utilization
of alloHCT from unrelated donors (URDs) in the United States, we calculated the number of patients diagnosed
with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance, Epidemiology and End
Results and 2007 US Census data, estimated the percentage of patients who would be eligible for URD alloHCT
after discounting the mortality rate during induction therapy and the rate of severe comorbidities, and
compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program. We found
that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11%
for multiple myeloma to 54% for chronic myeloid leukemia, with an average percentage of 26% for all the
disorders considered. In an analysis stratiﬁed by age groups (20 to 44, 45 to 64, and 65 to 74 years), the
utilization of URD alloHCT was higher in younger patients than in older patients for all disorders. Of acute
lymphoblastic and myeloid leukemia patients, approximately 66% underwent URD alloHCT later in the course
of their disease (in second or greater complete remission). URD alloHCT is likely underused for potentially
curable hematologic disorders, particularly in older patients. Understanding the reasons for low use of alloHCT
may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION it is estimated that the lifetime probability of undergoing
Allogeneic hematopoietic cell transplantation (alloHCT) is
accepted as a standard and potentially curative treatment
for selected hematologic disorders. Acute lymphoblastic
leukemia (ALL), acute myeloid leukemia (AML), chronic
lymphoid leukemia (CLL), chronic myeloid leukemia (CML),
Hodgkin’s lymphoma (HL), non-Hodgkin lymphoma (NHL),
multiple myeloma (MM), and myelodysplastic syndrome
(MDS) are among the most commonly transplanted diseases.
The 5-year disease-free survival rate using early alloHCT
ranges from <10% for ALL patients not in remission to
upward of 60% for high-risk AML patients in complete
remission (CR).
The National Marrow Donor Program (NMDP) has facili-
tated >50,000 alloHCTs with unrelated donor (URD) bone
marrow, blood stem cells, and cord blood units from its
inception in 1986 through 2011 (http://marrow.org/home.-
aspx). In addition to operating the world’s largest registry of
adult donors and cord blood units and facilitating URD
transplantation, the NMDP conducts research and provides
education for physicians and patients. Based on data from
the Center for International Blood and Marrow Trans-
plantation Research in the United States from 2001 to 2003,dgments on page 1463.
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13.06.014autologous (autoHCT) or alloHCT ranges from .23% to .98%
under different hypothetical scenarios of transplantation
type, donor availability, and indications of HCT in malig-
nancies treatable with HCT [1].
The number of URD alloHCTs facilitated by the NMDP
increases annually. However, 50% of patients for whom
a URD search is initiated do not go on to transplantation [2].
Many who could beneﬁt from alloHCT face barriers to being
offered transplantation or are offered transplantation too
late during their therapy. Even autoHCT may not be used for
patients with transplantable disorders such as MM or
recurrent NHL [3,4]. The reasons for these disparities are
likely multifactorial. The appropriate role and timing of
alloHCT varies by patient and disease characteristics.
Healthcare disparities can result from the lower utiliza-
tion of complex therapy such as cancer care [5-7]. Time from
diagnosis to transplantation is a major patient factor that
physicians can inﬂuence by referring patients for trans-
plantation early in the course of disease. There is a strong
relationship between earlier stage of disease at trans-
plantation and the likelihood of improved survival [8]. This
analysis examines the current use of URD alloHCT in the
United States for adult patients age 20 to 74 years.
METHODS
Estimation of the Transplantation-Eligible Population
The number of adult patients with hematologic malignancies, including
ALL, AML, CLL, CML, HL, NHL, MM, and MDS, who could be treated withTransplantation.
Table 1
Estimated Comorbidity Rate Considered to Disqualify Patients from
Consideration of Allogeneic Transplantation by Age Group
Comorbidities 20-44 Yr 45-64 Yr 65-74 Yr
Renal failure .005 .600 1.500
CVD 1.600 7.700 19.600
Pulmonary disease 6.750 4.300 4.300
Dementia .000 .700 1.500
Cancer* .003 .069 .256
Homelessness .300 .300 .300
Deep poverty 5.600 5.600 5.600
Suicide .619 .313 .313
Fatal motor vehicle accident .028 .019 .018
All conditions 15 20 33
CVD indicates cardiovascular disease.
* Cancer here indicates another cancer that would make alloHCT medi-
cally contraindicated (eg, metastatic lung cancer).
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miology and End Results (SEER) data from 2004 to 2008 (http://seer.can-
cer.gov/). The number of new cases of each malignancy in 2007 was
estimated using age-speciﬁc SEER incidence rates multiplied by the national
population at each age group from the 2007 population estimates of the US
Census Bureau (http://www.census.gov). Severe aplastic anemia is not
included in the SEER database and was not analyzed. We restricted the adult
population to 20 to 74 years of age as potential candidates for alloHCT.
Cure rates using alloHCT for adult transplantable hematologic disorders
depend on patient characteristics such as age, disease, stage of disease,
cytogenetic and molecular abnormalities, time from diagnosis to trans-
plantation, death during induction therapy, comorbidities, and amount of
prior therapy, including previous autoHCT [9-13]. Therefore, we estimated
the percentage of patients who could be potential and appropriate candi-
dates for alloHCT based on patient characteristics and potential outcomes
with ﬁrst-line therapies before determination of alloHCT eligibility. We
accounted for the following comorbidities, social factors, and conditions
resulting in prematuremortality that would limit the use of alloHCT: chronic
kidney disease (http://www.usrds.org/), cardiovascular diseases (http://
www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a1.htm), pulmonary
diseases [14], nontransplantable cancer (www.seer.gov), dementia [15],
homelessness (www.cbpp.org/cms/index.cfm?fa¼view&id¼2228), deep
poverty (www.cbpp.org/cms/index.cfm?fa¼view&id¼1290), suicide idea-
tion (http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6013a1.htm?s_cid¼
ss6013a1_e), and fatal motor vehicle crashes (http://www.census.
gov/compendia/statab/cats/transportation/motor_vehicle_accidents_and_
fatalities.html). To account for variable rates of comorbidities and conditions
that would limit their use of alloHCT in patients in different age groups, we
estimated the rate of the above comorbidities and conditions to be 15%, 20%,
and 33% in populations age 20 to 44, 45 to 64, and 65 to 74, respectively. The
rates of each comorbidity and condition considered by age group are shown
in Table 1. Accordingly, the eligible rate for alloHCTwas estimatedwithin the
same age groups after discounting the mortality rate during induction
therapy and the rate of comorbidities and conditions from each age group.
For adult ALL patients, approximately 8% die during induction therapy
[16]. The others with either standard or high-risk disease characteristics
would be considered eligible for alloHCT after induction therapy. After
excluding 15% to 33% of patients with comorbidities and conditions from the
92% of adult ALL patients who survived induction therapy, we estimated that
the remaining 78%, 74%, and 61% age 20 to 44, 45 to 64, and 65 to 74 years,
respectively, would be considered eligible for alloHCT [17,18]. For adult AML,
high-risk features include older age (>60 years), antecedent MDS, AML
secondary to prior chemotherapy or radiotherapy, failure to attain remission
with induction chemotherapy, and high-risk cytogenetics [19,20]. Approxi-
mately one half of all AML patients present at diagnosis with high-risk
cytogenetics and another 20% have chemotherapy-resistant disease [19],
yielding at least 70% of all AML patients age 20 to 74 years who would be
eligible for alloHCT. After excluding 11% of patients who die during induction
therapy, which is then reduced by an additional 15% to 33% due to severe
comorbidities and conditions, we estimated that the remaining 53%, 50%,
and 41% of patients age 20 to 44, 45 to 64, and 65 to 74 years, respectively,
would be eligible for alloHCT [21,22]. Because detailed information regarding
acute leukemia staging at the time of transplantation was available, as well
as detailed publications regarding acute leukemia risk,we examined ALL and
AML alloHCT indications and the number of URD transplantations in the
NMDP data from 2002 to 2006 in greater detail than other indications.
CLL is an adult cancer, usually not considered curable but rather
controllable with several immunotherapy and chemotherapy regimens [23].
High-risk CLL includes chromosome 11 and 17 abnormalities and >30% cellsurface expression of CD38 and ZAP70 [24]. These high-risk patients often do
not respond,orprogressearly, after treatmentwith low-dose immunotherapy
or chemotherapy regimens. We estimated that 6%, 6%, and 4% of CLL patients
age 20 to 44, 45 to 64, and 65 to 74 years, respectively, would be alloHCT-
eligible after discounting the rate of comorbidities [25,26]. For CML, 80% to
90% of patients respond to tyrosine kinase inhibitors and therefore would no
longer be considered for alloHCT [27]. CMLpatientswhowould be considered
for alloHCT are younger patients due to lower transplantation-related
mortality or patients in accelerated or blastic phase or who are resistant to
tyrosine kinase inhibitors [27,28]. We estimated that 9%, 8%, and 7% of CML
patients age 20 to 44, 45 to 64, and 65 to 74 years, respectively, would be
alloHCT candidates after discounting the rate of comorbidities [29-31].
For adult HL and NHL, chemotherapy and radiotherapy cure rates after
induction therapy are approximately 40% to 60% [32,33]. Those with
recurrent HL and NHL usually are treated with salvage chemotherapy fol-
lowed by autoHCT with cure rates between 30% and 60% [34,35]. Thus, HL
and NHL patients who relapse after autoHCT or those with very high-risk
features would be offered alloHCT. After further discounting the rate of
severe comorbidities and conditions, we estimated that 6%, 6%, and 5% of HL
patients and 10%, 10%, and 8% of NHL patients age 20 to 44, 45 to 64, and 65
to 74 years, respectively, would be alloHCT candidates [35,36].
MM is an adult cancer, usually not considered to be curable but is
controllable with induction chemotherapy often followed by autoHCT
[37-39]. Until recently, alloHCT forMMwas not considered as part of upfront
therapy and was usually reserved for relapsed and very high-risk patients
[37]. Some evidence shows that autoHCT followed by reduced-intensity
alloHCT may be superior to tandem autoHCT [40]. However, this study,
published in 2007, would not reﬂect standard clinical practice before 2007
and was not considered in our projection. Therefore, after discounting the
rate of severe comorbidities and conditions, we estimated that 6%, 6%, and
5% of MM patients age 20 to 44, 45 to 64, and 65 to 74 years, respectively,
would be alloHCT-eligible [41,42].
MDS is primarily an adult disorder that, until recently, has been treated
with supportive care or alloHCT in high-risk patients with suitable donors
[43,44]. Low-risk patients often received supportive care unless there was
transformation to higher-risk MDS or AML requiring therapy [43,44]. Aza-
citidine (2004) and decitabine (2006) were approved for use in MDS
patients with cytopenias [45-47]. Lenalidomide was approved in 2005 for
low and intermediate-1 MDS patients with cytogenetically abnormal kar-
otypes that included 5q deletion [48]. Patients who fail these therapies
would be considered alloHCT-eligible. After discounting the rate of severe
comorbidities and conditions, we estimated that 43%, 32%, and 20% of MDS
patients age 20 to 44, 45 to 64, and 65 to 74 years, respectively, would be
alloHCT-eligible [49,50].Estimation of Utilization of URD AlloHCT in the United States
Based on the total number of incident cases in adults between the ages
of 20 and 74 in 2007 and the percentage of patients eligible for alloHCT as
estimated above, we ﬁrst calculated the total number of patients eligible for
alloHCT for each hematologic malignancy. There is a 25% chance that any
two siblings will match at the MHC locus, speciﬁcally the HLA. Based on US
average family size, most patients will have 1 to 2 siblings. Therefore,
approximately 30% of transplantation-eligible patients are estimated to
have a suitably HLA-matched sibling donor (http://ibmtindy.com/word-
press/hla-typing/). Thus, approximately 70% of alloHCT-eligible patients will
not have a matched sibling. However, among the 30% of patients with
a matched sibling, we assume that 30% would be excluded from sibling
alloHCT due to severe comorbidities in the sibling. Based on these estimates,
21% of alloHCT patients will have an available sibling donor (21%); the
remaining patients should be considered potential URD alloHCT recipients.
We examined NMDP data for the actual number of alloHCTs performed
for each disease in 2007. Because the NMDP facilitates an estimated 90% of
all URD alloHCTs in the United States based on the number of NMDP-
facilitated URD alloHCTs as a percentage of the number of URD alloHCTs
reported to the World Marrow Donor Association (http://www.worldmar-
row.org), we thus adjusted the percentage of actual URD alloHCTs compared
with potential recipients by an adjustment factor of 1.11.RESULTS
Table 2 shows the incidence and numbers of transplant-
able hematologic disorders for adult patients age 20 to 44, 45
to 64, and 65 to 74 years based on 2007 SEER incidence and
the 2007 US population census. SEER data estimated a total
of 83,189 patients diagnosed with ALL, AML, CLL, CML, HL,
NHL, MM, and MDS between the ages of 20 and 74 in 2007.
Based on the estimates of eligible transplantation patients
Table 2
Estimated Usage of URD HCT by Transplantable Hematologic Disorders in 2007
Diagnosis Age
Group
(yr)
SEER Incidence
at Ages 20-74,
per 100,000*
Annual New
Diagnoses at
Ages 20-74y
Initially Eligible for
Consideration of
AlloHCT (%)
Estimated
Eligible for
AlloHCTz (%)
Estimated
Eligible for
AlloHCTx (N)
Sibling Donor
AlloHCTk (N)
Potential URD
Recipients{ (N)
Actual
NMDP
URD# (N)
Estimated
URD
Usage** (%)
ALL 20-44 .7-1.0 788 100 78 617 130 487 174 40
45-64 .7-1.1 677 100 74 501 105 396 77 22
65-74 1.4 276 100 61 169 36 134 2 2
Total .7-1.4 1741 74 1287 270 1017 253 28
AML 20-44 .9-1.7 1309 70 53 694 146 548 289 59
45-64 2.3-6.2 2923 70 50 1464 307 1157 404 39
65-74 9.5-14.3 2290 70 41 950 200 751 84 12
Total 0-21.3 6522 48 3108 653 2456 777 35
CLL 20-44 0-.6 192 8 6 12 3 10 6 69
45-64 1.8-10.9 3870 8 6 233 49 184 90 54
65-74 16.3-21.3 3647 8 5 182 38 144 18 14
Total 0-21.3 7710 6 428 90 338 114 37
CML 20-44 .4-1.1 750 10 9 64 13 50 46 100
45-64 1.4-2.7 1441 10 8 116 24 92 34 41
65-74 4.2-5.8 967 10 7 64 14 51 13 28
Total .4-5.8 3158 8 244 51 193 93 54
HL 20-44 3.0-4.5 3884 8 6 248 52 196 68 39
45-64 2.5-3.0 2019 8 6 122 26 96 15 17
65-74 3.9-4.4 812 8 5 41 9 32 2 7
Total 2.5-4.5 6715 6 410 86 324 85 29
NHL 20-44 2.4-10.5 5885 12 10 601 126 475 80 19
45-64 15.2-46.5 20,874 12 10 2014 423 1591 212 15
65-74 64.5-83.2 14,338 12 8 1146 241 905 25 3
Total 2.4-83.2 41,097 9 3761 790 2971 317 12
MM 20-44 0-1.7 596 8 6 38 8 30 13 48
45-64 3.3-15.2 6065 8 6 366 77 289 38 15
65-74 22.3-28.5 4934 8 5 246 52 195 2 1
Total 0-28.5 11,595 6 650 137 514 53 11
MDS 20-44 .1-.6 274 50 43 117 24 92 67 81
45-64 .9-5.4 1831 40 32 589 124 465 254 61
65-74 10-16.6 2546 30 20 509 107 402 36 10
Total .1-16.6 4651 26 1214 255 959 357 41
All disease 20-44 13,678 17 2391 502 1889 743 44
45-64 39,700 14 5404 1135 4269 1124 29
65-74 29,810 11 3307 695 2613 182 8
Total 83,189 13 11,102 2331 8771 2049 26
* The incidence is the number of annual newly diagnosed cases per 100,000 individuals between ages 20 and 74 based on SEER 2004-2008 data. Because SEER
data report incidence rate by 5-year age groups, the range within 20-44, 45-64, and 65-74 years is presented.
y The annual new diagnoses were estimated based on SEER age-speciﬁc incidence and 2007 intercensal population estimates as a sum of each 5-year age
group within 20-44, 45-64, and 65-74 years.
z The estimated percentage of potential patients eligible for alloHCT after discounting themortality rate during induction therapy (if applicable) and the rate of
comorbidities by age groups.
x The estimated number of potential alloHCT patients (% eligible  annual new diagnoses).
k The number of patients who could undergo sibling allogeneic transplantation (estimated at 21% based on the average number of children in US families and
the rate of comorbidities).
{ The number of patients who potentially could undergo URD HCT (estimated number of patients eligible for alloHCT minus number of patients who could
undergo URD HCT).
# Actual number of URD HCT facilitated by NMDP in 2007.
** Estimated percentage of URD usage in eligible patients after adjusting for 90% of URD facilitated by NMDP (actual number of NMDP URD/number of potential
URD/.90).
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patients. Among these alloHCT-eligible patients, 21% would
have sibling donors and 79% would have required a URD for
transplantation (N¼ 8771). The actual numberof patientswho
underwent unrelated alloHCT for the above diseaseswas 2049
(in 2007), which is only 26% of the estimated potential trans-
plantations after adjusting for the percentage of alloHCT
facilitated by the NMDP. Patients who underwent URD trans-
plantation as a percentage of the total URD candidates ranged
from 11% for MM and NHL to 54% for CML.
When stratiﬁed by age groups 20 to 44, 45 to 64, and 65 to
74 years, the estimated utilization rate of URD alloHCT was
consistently higher in younger patients than in older patients
(Figure 1). For CML patients age 20 to 44, all eligible patients
(100%) received transplantation, whereas the estimated
utilization rate in CML patients age 65 to 74was only 28%. For
all malignancies combined, the estimated utilization rate ofURD alloHCT was 44%, 29%, and 8% among patients age 20 to
44, 45 to 64, and 65 to 74 years, respectively. The estimated
number of potentially missing URD alloHCT by disease is
shown in Figure 2, with a range of 92 for CML and 2515 for
NHL.
As shown in Table 3, acute leukemia patients undergoing
transplantation were identiﬁed by disease type (ALL, AML)
and status (ﬁrst CR [CR1], CR2, and at least CR3, including
relapse). Most acute leukemia patients underwent URD
alloHCT late in the course of disease (65% CR2, including
relapse).
DISCUSSION
Based on cancer incidence data from SEER and data of
alloHCTs facilitated by the NMDP, we estimated the utiliza-
tion of URD alloHCTs in the United States for adult patients
diagnosed with ALL, AML, CLL, CML, HL, NHL, MM, and MDS
Figure 1. Bar graph of the estimated usage of URD HCT by transplantable hematologic disorders in 2007. Abbreviations: ALL¼Acute Lymphoblastic Leukemia;
AML¼Acute Myeloid Leukemia; CLL¼Chronic Lymphoid Leukemia; CML¼Chronic myeloid leukemia; HL¼Hodgkin Lymphoma; NHL¼Non-Hodgkin Lymphoma;
MM¼Multiple Myeloma; MDS¼Myelodysplastic Syndrome.
S. Yao et al. / Biol Blood Marrow Transplant 19 (2013) 1459e14641462considered to be eligible for alloHCT. Our results showed
underuse of alloHCT for all disorders, which varied from only
11% of eligible patients for MM to 54% for CML patients who
received a transplantation. We found that the utilization rate
of alloHCT was consistently higher in younger patients than
in older patients. Among ALL and AML patients, we further
showed that approximately two thirds underwent trans-
plantation at a late stage of their diseases (CR2 and higher). It
should be noted that our analysis was performed based on
data from 2007. In recent years, the use of URD alloHCT has
been signiﬁcantly improved, which may not be captured in
this study.
Between 30% and 50% of adult ALL patients present at the
time of initial diagnosis with high-risk cytogenetics, and the
rest of the standard-risk patients are at risk for recurrence
[17,51,52]. An international trial demonstrated that standard-
risk ALL patients (as deﬁned by age <35 years, cell type, and
elevated white blood cell count at diagnosis and not strati-
fying by cytogenetic risk) also beneﬁt from sibling alloHCT
[17]. The use of alloHCT remains uncertain for MM. A phase
III US study comparing tandem autoHCT with single autoHCT
followed by nonmyeloablative alloHCT showed no beneﬁt for
the alloHCT arm [53]. A European study demonstrated
a beneﬁt for alloHCT only after 5 years of follow-up, which
had not been reached in the US study [42]. Thus, there is
uncertaintywithin the transplantation community regarding
the role of alloHCT that likely affects referral of MM patients.
Relapsed HL and NHL patients are primarily treated with
autoHCT [34-36]. Patients relapsing after autoHCT and those
with very high-risk features would be considered alloHCTTable 3
Number of Acute Leukemia Cases by Disease Status and Percentage of Total
Undergoing URD AlloHCT from 2002 to 2006 in the NMDP Data
Disease N Percent
AML
CR1 989 35
CR2 719 25
CR3 and higher and relapse 1118 40
Total 2628 100
ALL
CR1 462 33
CR2 523 37
CR3 and higher and relapse 422 30
Total 1407 100and thus would comprise a small percentage of patients who
would undergo alloHCT. However, they comprise a large
number because of the high incidence of NHL. When we
examined the potential underuse by absolute numbers,
patients with ALL, AML, and NHL have the largest potential
for increasing the numbers of patients being offered poten-
tially curative transplantation.
Regardless of type of disease, not all potentially eligible
patients go on to alloHCT. A prospective study by the NMDP
in 2001 demonstrated that less than one half of all URD
preliminary searches resulted in an alloHCT in US and non-
US transplantation centers [2]. Reasons for not going on to
transplantation and the underuse of this curative therapy
include not being referred to a transplantation center by
physicians, searching too late in the course of disease (death
or progression with an active search), worsening patient
condition, prolonged search time, ﬁnancial issues, and no
suitable donor.
An example of a cause of delay in the donor search is the
lack of HLA typing at diagnosis for a chemotherapy-resistant
AML patient with no sibling donor. A delay of several weeks
could occur if a preliminary URD search was initiated after
failure of induction therapy. Another reason for delay could
be that the diagnosis of MDS has historically been absent
from the list of indications for alloHCT from the Centers forFigure 2. Bar graph of estimated number of potentially missing URD HCT by
transplantable hematologic disorders in 2007. Abbreviations: ALL¼Acute Lym-
phoblastic Leukemia; AML¼Acute Myeloid Leukemia; CLL¼Chronic Lymphoid
Leukemia; CML¼Chronic myeloid leukemia; HL¼Hodgkin Lymphoma;
NHL¼Non-HodgkinLymphoma;MM¼MultipleMyeloma;MDS¼Myelodysplastic
Syndrome.
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MDS for alloHCT or creates a delay in therapy due to
a coverage appeal decision. A Center for International Blood
and Marrow Transplantation Research study demonstrated
that older patients with MDS and AML had similar outcomes
after reduced-intensity alloHCT [54]. Since 2010, the Centers
for Medicare & Medicaid Services now covers MDS under
their Coverage with Evidence Development policy. An
example of not being referred early in the disease course is
patients with malignant hematologic disorders who often do
not undergo alloHCT until beyond CR1; most of these
patients are not treated with alloHCT. Although we consid-
ered some social factors, such as homelessness and suicide
ideation, in our estimation, some other potential factors were
not factored in, including caregiver and health insurance
issues, for lack of reliable statistics.
Variations in medical practice are not unique to cancer
care and are observed in all ﬁelds of medicine. Wide differ-
ences exist in the use of medical technology and the delivery
of medical care. Cancer care delivery can vary due to indi-
vidual physician decision making, regional differences in
technology use, patient preference, and socioeconomic
factors [5-7]. Although some medical practice differences
may not affect overall patient outcome, practice variations
may impact patient outcome in cancer care. Understanding
the reasons for low use of alloHCT may allow for the devel-
opment of strategies to increase the utilization of this cura-
tive therapy for patients with hematologic disorders.
In conclusion, our analysis clearly shows an underutili-
zation of alloHCT among patients with hematologic disor-
ders, particularly in older patients, and that among acute
leukemia patients, two thirds of patients underwent trans-
plantation at a late stage of their diseases, resulting in lower
survival rates than if transplanted at an earlier stage. Future
studies arewarranted to identify barriers for the low usage of
this curative therapy and to develop strategies to overcome
these barriers.
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